Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"Is the Clinical Application of CXCR4 Imaging in the Diagnosis and Management of Primary Aldosteronism Really Happening?","authors":"Xiang Li, Jie Ding, Stefanie Hahner, Martin Reincke, Marcus Hacker, Constantin Lapa, Li Huo","doi":"10.2967/jnumed.124.268145","DOIUrl":"10.2967/jnumed.124.268145","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1681-1684"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma.","authors":"Maria C Ferrández, Sandeep S V Golla, Jakoba J Eertink, Sanne E Wiegers, Gerben J C Zwezerijnen, Martijn W Heymans, Pieternella J Lugtenburg, Lars Kurch, Andreas Hüttmann, Christine Hanoun, Ulrich Dührsen, Sally F Barrington, N George Mikhaeel, Luca Ceriani, Emanuele Zucca, Sándor Czibor, Tamás Györke, Martine E D Chamuleau, Josée M Zijlstra, Ronald Boellaard","doi":"10.2967/jnumed.124.268191","DOIUrl":"10.2967/jnumed.124.268191","url":null,"abstract":"<p><p>The aim of this study was to validate a previously developed deep learning model in 5 independent clinical trials. The predictive performance of this model was compared with the international prognostic index (IPI) and 2 models incorporating radiomic PET/CT features (clinical PET and PET models). <b>Methods:</b> In total, 1,132 diffuse large B-cell lymphoma patients were included: 296 for training and 836 for external validation. The primary outcome was 2-y time to progression. The deep learning model was trained on maximum-intensity projections from PET/CT scans. The clinical PET model included metabolic tumor volume, maximum distance from the bulkiest lesion to another lesion, SUV_peak, age, and performance status. The PET model included metabolic tumor volume, maximum distance from the bulkiest lesion to another lesion, and SUV_peak Model performance was assessed using the area under the curve (AUC) and Kaplan-Meier curves. <b>Results:</b> The IPI yielded an AUC of 0.60 on all external data. The deep learning model yielded a significantly higher AUC of 0.66 (<i>P</i> < 0.01). For each individual clinical trial, the model was consistently better than IPI. Radiomic model AUCs remained higher for all clinical trials. The deep learning and clinical PET models showed equivalent performance (AUC, 0.69; <i>P</i> > 0.05). The PET model yielded the highest AUC of all models (AUC, 0.71; <i>P</i> < 0.05). <b>Conclusion:</b> The deep learning model predicted outcome in all trials with a higher performance than IPI and better survival curve separation. This model can predict treatment outcome in diffuse large B-cell lymphoma without tumor delineation but at the cost of a lower prognostic performance than with radiomics.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1802-1807"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of ¹⁸F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer.","authors":"Jeongryul Ryu, Jaewon Hyung, Sangwon Han, Jae Ho Jeong, Sae Byul Lee, Tae-Kyung Robyn Yoo, Jisun Kim, Hee Jeong Kim, Il Yong Chung, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Hyehyun Jeong, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Dae Hyuk Moon","doi":"10.2967/jnumed.124.267913","DOIUrl":"10.2967/jnumed.124.267913","url":null,"abstract":"<p><p>The clinical impact of 16α-¹⁸F-fluoro-17β-estradiol (¹⁸F-FES) PET/CT on patient management has not been well investigated. The aim of this study was to assess the clinical impact of ¹⁸F-FES PET/CT on the management of patients with recurrent or metastatic breast cancer. <b>Methods:</b> Study subjects were identified retrospectively from a database of a prospective trial for postmarketing surveillance of ¹⁸F-FES between 2021 and 2023. Patients who were suspected or known to have recurrent or metastatic estrogen receptor-positive breast cancer based on a routine standard workup were included. Planned management before and actual management after ¹⁸F-FES PET/CT were assessed by 2 experienced medical oncologists via medical chart review. A 5-point questionnaire was provided to evaluate the value of ¹⁸F-FES PET/CT for management planning. The rate of intention-to-treat and interdisciplinary changes, and the impact of ¹⁸F-FES PET/CT according to PET/CT result or clinical indication, were examined. <b>Results:</b> Of the 344 included patients, 120 (35%) experienced a change in management after ¹⁸F-FES PET/CT. In 139 (40%) patients,¹⁸F-FES PET/CT supported the existing management decision without a change in management. Intention-to-treat and interdisciplinary changes accounted for 64% (77/120) and 68% (82/120) of all changes, respectively. A higher rate of change was observed when lesions were ¹⁸F-FES-negative (44% [36/81]) than ¹⁸F-FES-positive (30% [51/172]) or mixed ¹⁸F-FES-positive/negative (36% [33/91]). Regarding clinical indications, the highest rate of change was shown when evaluating the origins of metastasis of double primary cancers (64% [9/14]). <b>Conclusion:</b> ¹⁸F-FES PET/CT modified the management of recurrent or metastatic breast cancer, serving as an impactful imaging modality in clinical practice.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1689-1694"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.","authors":"Jeremie Calais, Michael J Morris, Ayse Tuba Kendi, Arash Rezazadeh Kalebasty, Ronald Tutrone, Michael J Anderson, Oliver Sartor","doi":"10.2967/jnumed.124.268363","DOIUrl":"10.2967/jnumed.124.268363","url":null,"abstract":"<p><p>Optimal patient management protocols for metastatic castration-resistant prostate cancer (mCRPC) are poorly defined and even further complexified with new therapy approvals, such as radiopharmaceuticals. The prostate-specific membrane antigen (PSMA)-targeted agent ¹⁷⁷Lu vipivotide tetraxetan ([¹⁷⁷Lu]Lu-PSMA-617), approved after the phase III VISION study, presents physicians with additional aspects of patient management, including specific adverse event (AE) monitoring and management, as well as radiation safety. Drawing on our experience as VISION study investigators, here we provide guidance on best practices for delivering PSMA-targeted radiopharmaceutical therapy (RPT) to patients with mCRPC. After a comprehensive review of published evidence and guidelines on RPT management in prostate cancer, we identified educational gaps in managing the radiation safety and AEs associated with [¹⁷⁷Lu]Lu-PSMA-617. Our results showed that providing sufficient education on AEs (e.g., fatigue and dry mouth) and radiation safety principles is key to effective delivery and management of patient expectations. Patient counseling by health care professionals, across disciplines, is a cornerstone of optimal patient management during PSMA-targeted RPT. Multidisciplinary collaboration is crucial, and physicians must adhere to radiation safety protocols and counsel patients on radiation safety considerations. Treatment with [¹⁷⁷Lu]Lu-PSMA-617 is generally well tolerated; however, additional interventions may be required, such as dosing modification, medications, or transfusions. Urinary incontinence can be challenging in the context of radiation safety. Multidisciplinary collaboration between medical oncologists and nuclear medicine teams ensures that patients are monitored and managed safely and efficiently. In clinical practice, the benefit-to-risk ratio should always be evaluated on a case-by-case basis.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1666-1671"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison Between Brain and Cerebellar Autoradiography Using [¹⁸F]Flortaucipir, [¹⁸F]MK6240, and [¹⁸F]PI2620 in Postmortem Human Brain Tissue.","authors":"Antonio Aliaga, Joseph Therriault, Kely Monica Quispialaya, Arturo Aliaga, Robert Hopewell, Nesrine Rahmouni, Arthur C Macedo, Peter Kunach, Jean-Paul Soucy, Gassan Massarweh, Aida Abreu Diaz, Tharick A Pascoal, Andreia Rocha, Marie-Christine Guiot, Luiza S Machado, Marco Antônio De Bastiani, Débora Guerini de Souza, Diogo O Souza, Serge Gauthier, Eduardo R Zimmer, Pedro Rosa-Neto","doi":"10.2967/jnumed.124.267539","DOIUrl":"https://doi.org/10.2967/jnumed.124.267539","url":null,"abstract":"<p><p>Our objective was to evaluate the in vitro binding properties of [¹⁸F]flortaucipir, 6-(fluoro-¹⁸F)-3-(1<i>H</i>-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([¹⁸F]MK6240), and 2-(2-([¹⁸F]fluoro)pyridin-4-yl)-9<i>H</i>-pyrrolo[2,3-b:4,5c']dipyridine ([¹⁸F]PI2620) head-to-head in postmortem human brain tissue. <b>Methods:</b> Autoradiography was used to assess uptake of [¹⁸F]flortaucipir, [¹⁸F]MK6240, and [¹⁸F]PI2620 in control and Alzheimer disease (AD) autopsy-confirmed brain tissues. The study focused on the analysis of the prefrontal cortex, hippocampus, and cerebellum sections in 12 controls and 12 AD cases, as well as whole-brain hemisphere in 1 control and 1 AD sample, for each radiotracer. The binding values of [¹⁸F]flortaucipir, [¹⁸F]MK6240, and [¹⁸F]PI2620 were calculated from regions of interest manually drawn in the prefrontal, hippocampal, and cerebellar cortices. <b>Results:</b> For all 3 radioligands investigated, we observed significant tracer binding differences between control and AD tissues in the whole-brain hemisphere, prefrontal cortex, and hippocampus but not in the cerebellar cortex. [¹⁸F]MK6240 and [¹⁸F]PI2620 had higher effect sizes to differentiate control and AD cases than did [¹⁸F]flortaucipir. Bland-Altman analyses revealed strong correlations between [¹⁸F]MK6240, [¹⁸F]PI2620, and [¹⁸F]flortaucipir, with the highest agreement found for [¹⁸F]MK6240 versus [¹⁸F]PI2620. <b>Conclusion:</b> The 3 radioligands showed comparable diagnostic properties to assess tau aggregates in vitro. Binding to AD brain tissues was higher for [¹⁸F]MK6240 and [¹⁸F]PI2620 than for [¹⁸F]flortaucipir. Additionally, [¹⁸F]MK6240 and [¹⁸F]PI2620 had greater selectivity, displaying decreased uptake in control brain tissue compared with [¹⁸F]flortaucipir. These results might provide insights on ongoing initiatives to create a universal scale for tau imaging studies.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with ²¹³Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.","authors":"Andreas Helisch, Clemens Kratochwil, Christian Kleist, Susanne Krämer, Juan Jose Rosales Castillo, Katharina Dendl, Hendrik Rathke, Isabelle von Goetze, Mathias Schreckenberger, Dirk Jäger, Thomas Lindner, Walter Mier, Frederik Giesel, Uwe Haberkorn, Manuel Röhrich","doi":"10.2967/jnumed.124.268386","DOIUrl":"https://doi.org/10.2967/jnumed.124.268386","url":null,"abstract":"<p><p>Radiopharmaceutical therapies (RPTs) based on fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) are a new option for progressive metastatic cancer in patients pretreated multiple times. To date, published in-human data refer to initial experiences with β-emitting ⁹⁰Y- and ¹⁷⁷Lu-based RPT. However, the short tumor retention time of FAPI ligands is considered a major limitation of FAPI RPT. Therefore, fractionated FAPI RPT with ²¹³Bi, an α-emitter with a half-life of 46 min, appears to be a promising FAPI RPT regimen. Here, we report on our initial experiences with regard to the feasibility, tolerability, and response of fractionated ²¹³Bi-FAPI-46 RPT. <b>Methods:</b> Six patients (4 women and 2 men) with progressive metastatic solid tumors (3 colon cancer, 1 anal cancer, 1 breast cancer, and 1 prostate cancer) aged 16-77 y were treated with a mean of 1,609 MBq of ²¹³Bi-FAPI-46, fractionated into 53 single applications (range, 5-12 RPT applications per patient; mean, 8.8 applications) over a period of up to 107 h per patient. Of the 6 patients, 4 patients received adjuvant treatment with pembrolizumab. ¹⁸F-FDG (4 patients) and ⁶⁸Ga-FAPI-46 (5 patients) PET/CT scans were performed before and after RPT. PET images were assessed visually and by calculating total lesion glycolysis and total lesion FAPI. <b>Results:</b> RPT with ²¹³Bi-FAPI-46 was well tolerated without adverse side effects. In terms of visual response assessment, there was 1 partial response (16.7%), 1 patient with stable disease (16.7%), and 4 patients with progressive disease (66.7%). Concordantly, total lesion glycolysis and total lesion FAPI were decreased in the responding patient (not applicable and -24.3%, respectively), slightly decreased in the patient with stable disease (-10.6% and -5.9%, respectively), and increased in the 4 patients with progression (mean, +104.4% and +321.3%, respectively). <b>Conclusion:</b> Fractionated FAPI RPT with the short-half-life α-emitter ²¹³Bi-FAPI-46 is a promising approach that matches the pharmacokinetics of FAPI-46 better than the ¹⁷⁷Lu- or ⁹⁰Y-labeled compounds. In this pilot project, fractionated RPT with ²¹³Bi-FAPI-46 showed good clinical tolerability and even led to regressive or stable disease in the short term in 2 of 6 patients. Further studies with larger patient cohorts are required to evaluate the actual efficacy and long-term effects of this variant of FAPI RPT.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted ¹⁸F-Fluorthanatrace PET in Breast Cancer.","authors":"Anthony J Young, Austin R Pantel, Mahsa Kiani, Robert K Doot, Sina Bagheri, Daniel A Pryma, Michael D Farwell, Shihong Li, Hsiaoju Lee, Erin K Schubert, Anthony Secreto, Samantha P Zuckerman, Anupma Nayak, Hoon Choi, Sean Carlin, Angela DeMichele, David A Mankoff, Rong Zhou, Robert H Mach, Elizabeth S McDonald","doi":"10.2967/jnumed.124.268254","DOIUrl":"https://doi.org/10.2967/jnumed.124.268254","url":null,"abstract":"<p><p>The poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have demonstrated efficacy in ovarian, breast, and prostate cancers, but current biomarkers do not consistently predict clinical benefit. ¹⁸F-fluorthanatrace (¹⁸F-FTT) is an analog to rucaparib, a clinically approved PARPi, and is a candidate biomarker for PARPi response. This study intends to characterize ¹⁸F-FTT pharmacokinetics in breast cancer and optimize image timing for clinical trials. A secondary aim is to determine whether ¹⁸F-FTT uptake in breast cancer correlates with matched frozen surgical specimens as a reference standard for PARP-1 protein. <b>Methods:</b> Thirty prospectively enrolled women with a new diagnosis of breast cancer were injected with ¹⁸F-FTT and imaged dynamically 0-60 min after injection over the chest, with an optional static scan over multiple bed positions starting around 70 min. Kinetic analysis of lesion uptake was performed using blood-pool activity with population radiometabolite corrections. Normal breast and normal muscle reference tissue models were compared with PARP-1 protein expression in 10 patients with available tissue. Plasma radiometabolite concentrations and uptake in tumor and normal muscle were investigated in mouse xenografts. <b>Results:</b> Pharmacokinetics of ¹⁸F-FTT were well fit by Logan plot reference region models of reversible binding. However, fits of 2-tissue compartment models assuming negligible metabolite uptake were unstable. Rapid metabolism of ¹⁸F-FTT was demonstrated in mice, and similar uptake of radiometabolites was found in tumor xenografts and normal muscle. Tumor ¹⁸F-FTT distribution volume ratios relative to normal muscle reference tissue correlated with tissue PARP-1 expression (<i>P</i> < 0.02, <i>n</i> = 10). The tumor-to-normal muscle ratio from a 5-min frame between 50 and 60 min after injection, a potential static scan protocol, closely corresponded to the distribution volume ratio relative to normal muscle and correlated to PARP-1 expression (<i>P</i> < 0.02, <i>n</i> = 10). <b>Conclusion:</b> This study of PARPi analog ¹⁸F-FTT showed that uptake kinetics in vivo corresponded to expression of PARP-1 and that ¹⁸F-FTT quantitation is influenced by radiometabolites that are increasingly present late after injection. Radiometabolites can be controlled by using optimal image acquisition timing or normal muscle reference tissue modeling in dynamic imaging or a tumor-to-normal muscle ratio. Optimal image timing for tumor-to-normal muscle quantification in humans appears to be between 50 and 60 min after injection. Therefore, a clinically practical static imaging protocol commencing 45-55 min after injection may sufficiently balance ¹⁸F-FTT uptake with background clearance and radiometabolite interference for quantitative interpretation of PARP-1 expression in vivo.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04-Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms.","authors":"Kerstin Michalski, Aleksander Kosmala, Philipp E Hartrampf, Marieke Heinrich, Sebastian E Serfling, Wiebke Schlötelburg, Andreas K Buck, Alexander Meining, Rudolf A Werner, Alexander Weich","doi":"10.2967/jnumed.124.268288","DOIUrl":"https://doi.org/10.2967/jnumed.124.268288","url":null,"abstract":"<p><p>We aimed to quantitatively investigate the prognostic value of PET-based biomarkers on [¹⁸F]FDG and [⁶⁸Ga]Ga-fibroblast activation protein inhibitor (FAPI)-04 PET/CT in patients with highly aggressive neuroendocrine neoplasms (NENs) and to compare the visually assessed differences in uptake on both examinations with progression-free survival (PFS). <b>Methods:</b> In this single-center retrospective analysis, 20 patients with high-grade NENs had undergone [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04 PET. Both PET scans were visually compared, and the presence of [¹⁸F]FDG-positive, [⁶⁸Ga]Ga-FAPI-04-negative (FDG+/FAPI-) lesions was noted. In addition, we assessed maximum, peak, and mean SUV; tumor volume (TV); and total lesion uptake (TLU = TV × SUV_mean) for both radiotracers using a 40% lesion-based threshold. The results of quantitative and visual analysis were correlated with PFS using log-rank analysis or univariate Cox regression. PFS was defined radiographically using RECIST 1.1., clinically using signs of disease progression, or as death. <b>Results:</b> Most primary tumors were located in the gastrointestinal tract (13/20 patients, 65%) or were cancer of unknown primary (5/20 patients, 25%). FDG+/FAPI- lesions were found in 9 of 20 patients (45%). Patients with FDG+/FAPI- lesions had a significantly decreased PFS of 4 mo, compared with 9 mo for patients without FDG+/FAPI- metastases (<i>P</i> = 0.0063 [log-rank test]; hazard ratio [HR], 5.637; 95% CI 1.619-26.16; <i>P</i> = 0.0110 [univariate Cox regression]). On univariate analysis, a significant correlation was also found between PFS and TV for both radiotracers ([¹⁸F]FDG: mean TV, 258 ± 588 cm³; HR, 1.024 [per 10 cm³]; 95% CI, 1.007-1.046; <i>P</i> = 0.0204) ([⁶⁸Ga]Ga-FAPI-04: mean TV, 130 ± 192 cm³; HR, 1.032 [per 10 cm³]; 95% CI, 1.001-1.062; <i>P</i> = 0.0277) and TLU on [¹⁸F]FDG PET (mean TLU, 1,931 ± 4,248 cm³; HR, 1.004 [per 10 cm³]; 95% CI, 1.001-1.007; <i>P</i> = 0.0135). <b>Conclusion:</b> The presence of discordant FDG+/FAPI- lesions is associated with a significantly shorter PFS, which might indicate more aggressive disease prone to early progression. Dual-tracer PET/CT of patients with highly aggressive NENs could help guide treatment decisions or identify high-risk lesions for additional local therapeutic approaches.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.","authors":"Rong Rong Huang, Chunlai Zuo, Christine E Mona, Adrien Holzgreve, Colm Morrissey, Peter S Nelson, Lauren Brady, Lawrence True, Anthony Sisk, Johannes Czernin, Jeremie Calais, Huihui Ye","doi":"10.2967/jnumed.124.268037","DOIUrl":"https://doi.org/10.2967/jnumed.124.268037","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) is a theranostic target for metastatic prostate cancer (PCa). However, castration-resistant PCa (CRPC) may lose PSMA expression after systemic therapy. Fibroblast activation protein (FAP), expressed by carcinoma-associated fibroblasts in various cancer types, including PCa, has the potential to be an alternative target. In this study, we evaluated FAP expression in CRPC to assess its potential, using PSMA as a comparison. <b>Methods:</b> FAP expression was assessed using immunohistochemistry in 116 CRPC tumors: 78 adenocarcinomas, 11 small cell carcinomas, and 27 anaplastic carcinomas. Correlation analysis between manual scoring and automated scoring was performed on 54 whole-slide sections of metastatic CRPC. Paired FAP and PSMA stains were assessed in tissue microarray cores of CRPC (<i>n</i> = 62), consisting of locally advanced CRPC (<i>n</i> = 9) and metastatic CRPC (<i>n</i> = 53). FAP and PSMA positivity was defined by an immunohistochemistry score of at least 10. To explore the correlation of PSMA and FAP inhibitor (FAPi) PET imaging and immunohistochemistry, a preliminary analysis of 4 patients included in a [⁶⁸Ga]-FAPi-46 imaging trial (NCT04457232) was conducted. <b>Results:</b> Manual and automated scoring of FAP yielded results with strong correlations. Overall, FAP expression in CRPC was notably lower than PSMA expression (median immunoscores, 14 vs. 72; <i>P</i> < 0.001). Different histologic subtypes of CRPC demonstrated distinct levels of PSMA expression, whereas their FAP expression levels were comparable. Among the 19 PSMA-negative tumors, 11 (58%) exhibited FAP positivity. FAP expression levels in lymph node metastases were significantly lower than those in nonnodal metastases (<i>P</i> = 0.021). Liver metastases showed significant enrichment of tumors with strong FAP expression compared with nonliver lesions (<i>P</i> = 0.016). In the 4 clinical trial patients, the biopsied metastatic lesions showed lower uptake on FAPi PET than on PSMA PET (median SUV_max, 9.6 vs. 14.5), consistent with FAP expression that was lower than PSMA expression in the corresponding tumor biopsy samples (median immunoscores, 30 vs. 160). <b>Conclusion:</b> Because of the low FAP expression levels in CRPC, the utility of FAPi PET imaging may be limited. Although FAPi PET imaging may be further tested in PSMA-negative CRPC, such as small cell carcinoma, other molecular imaging modalities should be evaluated as alternative choices.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.","authors":"Ida Sonni, Adam B Weiner, Sahith Doddipalli, Madhvi Deol, David Ban, Hye Ok Kim, Tristan Grogan, Preeti Ahuja, Nashla Barroso, Yang Zong, Priti Soin, Anthony Sisk, Johannes Czernin, William Hsu, Jeremie Calais, Robert E Reiter, Steven S Raman","doi":"10.2967/jnumed.124.268443","DOIUrl":"https://doi.org/10.2967/jnumed.124.268443","url":null,"abstract":"<p><p>Multiparametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) PET/CT are complementary imaging modalities used in the presurgical evaluation of patients with prostate cancer (PCa). The purpose of this study was to characterize clinically significant PCa (csPCa) detected and not detected by PSMA PET/CT and mpMRI, focusing on tumors detected solely by PSMA PET/CT and overlooked by mpMRI. <b>Methods:</b> We conducted a single-center, retrospective analysis of patients who underwent both PSMA PET/CT and mpMRI within 3 mo of each other and before radical prostatectomy. Two nuclear medicine physicians and 2 radiologists, in a masked manner, independently contoured PCa lesions on PSMA PET/CT and mpMRI, respectively. A consensus read was done with a third reader for each modality, and a majority rule was applied (2:1). After centralized imaging, a pathologic review was done by a genitourinary pathologist. We assessed agreement between imaging modalities and correlation with pathology. Logistic regression models explored associations between clinicopathologic variables and tumor detection on imaging. <b>Results:</b> In total, 132 csPCa tumors from 100 patients were identified on surgical pathology. PSMA PET/CT showed higher lesion-level (87% vs. 80%) and patient-level (98% vs. 94%) sensitivity than mpMRI. Tumors detected on both imaging modalities were larger and had higher grade groups than those not detected by one or both imaging modalities. On multivariable analysis, csPCa tumors undetected by mpMRI but detected by PSMA PET/CT were smaller than those detected by both modalities. Most tumors showing aggressive pathologic features, such as the large cribriform pattern (94.7%) and the intraductal carcinoma (96%), were correctly detected by both imaging modalities. Limitations included selection bias in a surgical cohort. <b>Conclusion:</b> PSMA PET/CT tends to detect smaller csPCa not detected by mpMRI. Larger tumors on pathology with higher grade groups are more likely to be correctly detected by both imaging modalities. These findings provide insights for refining presurgical evaluation strategies in PCa.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}